Immunovant, Inc.
IMVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001764013
In the last 90 days, Immunovant, Inc. insiders filed 0 open-market purchases and 10 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.25B in total; Greenlight Capital is the only superinvestor holding it.
13F holders, Q1 2025
Institutional positions in Immunovant, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 194
- +9 vs. Q4 2024
- Shares held
- 94.8M
- +15.5M (+19.6%) vs. Q4 2024
- Total value
- $1.62B
- −$342.0M (−17.4%) vs. Q4 2024
- New holders
- 36
- 91 more added
- Sold out
- 27
- 43 more reduced
2 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IMVT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 226 | $4.25B |
| Q1 2026 | 216 | $2.75B |
| Q4 2025 | 197 | $2.76B |
| Q3 2025 | 186 | $1.53B |
| Q2 2025 | 169 | $1.54B |
| Q1 2025 | 194 | $1.62B |
| Q4 2024 | 187 | $1.98B |
| Q3 2024 | 182 | $2.26B |
| Q2 2024 | 197 | $1.97B |
| Q1 2024 | 209 | $2.27B |
| Q4 2023 | 228 | $2.88B |
| Q3 2023 | 181 | $2.57B |
| Q2 2023 | 147 | $1.05B |
| Q1 2023 | 142 | $903.7M |
| Q4 2022 | 133 | $1.00B |
| Q3 2022 | 112 | $238.1M |
| Q2 2022 | 94 | $156.5M |
| Q1 2022 | 112 | $218.6M |
| Q4 2021 | 118 | $322.4M |
| Q3 2021 | 119 | $293.6M |
| Q2 2021 | 110 | $407.5M |
| Q1 2021 | 120 | $654.3M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Immunovant, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Caption Management, LLC | 0 | $0 | 0.00% | −86,760−100.0% | Sold out |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −78,500−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −45,100−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −34,731−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −31,896−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −22,740−100.0% | Sold out |
| F/M Investments LLC | 0 | $0 | 0.00% | −20,573−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −10,900−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −10,898−100.0% | Sold out |
| Jain Global LLC | 0 | $0 | 0.00% | −10,111−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −8,907−100.0% | Sold out |
| Pictet & Cie (Europe) SA | 0 | $0 | 0.00% | −8,089−100.0% | Sold out |
| Virtus ETF Advisers LLC | 0 | $0 | 0.00% | −2,577−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −600−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −570−100.0% | Sold out |
| BFSG, LLC | 0 | $0 | 0.00% | −565−100.0% | Sold out |
| Aster Capital Management (DIFC) Ltd | 0 | $0 | 0.00% | −190−100.0% | Sold out |
| Ci Investments Inc. | 0 | $0 | 0.00% | −106−100.0% | Sold out |
| Comerica Bank | 0 | $0 | 0.00% | −96−100.0% | Sold out |
| Bessemer Group Inc | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Bryn Mawr Trust Co | 0 | $0 | 0.00% | −24−100.0% | Sold out |
| Nuveen Asset Management, LLC | – | – | – | – | Not filed |
| Cassady Schiller Wealth Management, LLC | – | – | – | – | Not filed |